Fabry U - Search Results

1

Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.

Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R, Büll U. Cremerius U, et al. Among authors: fabry u. Nuklearmedizin. 2001 Feb;40(1):23-30. Nuklearmedizin. 2001. PMID: 11373935

2

[Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].

Thill R, Neuerburg J, Fabry U, Cremerius U, Wagenknecht G, Hellwig D, Osieka R, Günther R, Büll U. Thill R, et al. Among authors: fabry u. Nuklearmedizin. 1997 Oct;36(7):234-9. Nuklearmedizin. 1997. PMID: 9441282 German.

3

Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma.

Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Cremerius U, et al. Among authors: fabry u. Nucl Med Commun. 1998 Nov;19(11):1055-63. doi: 10.1097/00006231-199811000-00005. Nucl Med Commun. 1998. PMID: 9861622

4

[Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].

Cremerius U, Fabry U, Kröll U, Zimny M, Neuerburg J, Osieka R, Büll U. Cremerius U, et al. Among authors: fabry u. Nuklearmedizin. 1999;38(1):24-30. Nuklearmedizin. 1999. PMID: 9987778 German.

5

Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.

Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B, Schaefer W, Buell U, Osieka R. Cremerius U, et al. Among authors: fabry u. Bone Marrow Transplant. 2002 Jul;30(2):103-11. doi: 10.1038/sj.bmt.1703607. Bone Marrow Transplant. 2002. PMID: 12132049 Clinical Trial.

6

Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells.

Efferth T, Fabry U, Glatte P, Osieka R. Efferth T, et al. Among authors: fabry u. J Cancer Res Clin Oncol. 1995;121(11):648-56. doi: 10.1007/BF01218522. J Cancer Res Clin Oncol. 1995. PMID: 7593128

7

Anti-Fas/Apo-1 monoclonal antibody CH-11 depletes glutathione and kills multidrug-resistant human leukemic cells.

Efferth T, Fabry U, Osieka R. Efferth T, et al. Among authors: fabry u. Blood Cells Mol Dis. 1996;22(1):2-9; discussion 10. doi: 10.1006/bcmd.1996.0002. Blood Cells Mol Dis. 1996. PMID: 8807081

8

DNA damage and apoptosis in mononuclear cells from glucose-6-phosphate dehydrogenase-deficient patients (G6PD Aachen variant) after UV irradiation.

Efferth T, Fabry U, Osieka R. Efferth T, et al. Among authors: fabry u. J Leukoc Biol. 2001 Mar;69(3):340-2. J Leukoc Biol. 2001. PMID: 11261779

9

Thrombocytopenia or giant platelets?

Fabry U, Lammert F, Osieka R. Fabry U, et al. Lancet. 2003 Mar 1;361(9359):735. doi: 10.1016/S0140-6736(03)12657-8. Lancet. 2003. PMID: 12620737 No abstract available.

10

Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.

Efferth T, Fabry U, Osieka R. Efferth T, et al. Among authors: fabry u. Anticancer Res. 2002 Jan-Feb;22(1A):231-4. Anticancer Res. 2002. PMID: 12017294

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters